LDS/Medical Tests/Acute Myeloid Leukemia (AML), FISH, Blood

Acute Myeloid Leukemia (AML), FISH, Blood

AML is generally an elderly disease with an incidence of 25/100,000 persons in octogenarians. Its frequency in childhood is about 0.4/100,000. AML comprises 20% of acute leukemias in children and 80% in adults. The most common symptoms include anemia, thrombocytopenia, fever, hepatomegaly and/or splenomegaly (25%) and less than 5 × 109/L leukocyte count (50%).

AML is often caused by chromosomal abnormalities including translocations and deletions and mutations. The multiple recurrent chromosome abnormalities in AML are observed in approximately 60% of AML cases. The most common chromosome abnormalities associated with AML include t(8;21), t(15;17), inv(16), +8, t(6;9), t(8;16), t(1;22), t(9;22), t(3;5) and abnormalities of the MLL gene at 11q23. The most common translocations and gene amplifications are associated mainly with MLL and include AFF1- t(4;11), MLTT4- t(6;11), MLLT3- t(9;11), MLLT10- t(10;11), CREBBP- t(11;16), ELL- t(11;19p13.1), and MLLT1- t(11;19p13.3). AML can also evolve from chromosome abnormalities associated with MDS including inv(3), -5/5q-, -7/7q-, +8, 13q-, 17p-, 20q-, t(1;3), and t(3;21).

The t(8;21)(q22;q22.3) RUNX1-RUNX1T1 abnormality is found in approximately 10% of all AML cases, and patients who harbor this abnormality are considered to have AML regardless of the percentage of blasts in the bone marrow. The inv(16)(p13.1q22) or t(16;16)(p13.1;q22) CBFβ-MYH11 rearrangements are seen in approximately 5% of all cases of adult AML. The t(15;17)(q24.1;q21.1) PML-RARα aberration is basically synonymous with the diagnosis of acute promyelocytic leukemia (APL, AML-M3). It comprises about 9% of all cases of AML. The inv(3)(q21q26.2) or t(3;3)(q21;q26.2) RPN1-EVI1 has 2% incidence in AML. The t(6;9)(p23;q34) DEK-NUP214 is associated with acute megakaryoblastic leukemia with about 1% occurrence mostly in infants and young children. Trisomy 8, del (5q)/t(5q), −7 or del(7q) abnormalities have a relatively higher frequency with 10-15%, 12%, and 14% incidence, respectively. The t(v;11)(v;q23.3) MLL rearrangement is seen 5-8% of cases of AML.

Fluorescence in situ hybridization (FISH) is a method for identification of chromosomal aberrations by usage of specific DNA probes against particular DNA sequences in the nucleus of interphase cells or metaphase chromosomes.

In a clinical setting, the first step is cytogenetic analysis to identify the chromosomal abnormalities. Conventional chromosome analysis is the gold standard for identification of the common, recurrent chromosome abnormalities in AML; however, some of the subtle rearrangements can be missed (e.g. inv[16] and MLL abnormalities). FISH analysis of nonproliferating (interphase) cells with specific probes could detect the common chromosome abnormalities, residual disease, early relapse, and follow-up of therapy in patients with AML.

  • Detection and identification of important chromosomal aberration(s) with prognostic effect in acute myeloid leukemia
  • Disease management and response to therapy
  • As an adjunct to conventional chromosome studies in acute myeloid leukemia
  • Chromosomal abnormalities or a neoplastic clone is detected when the percentage of cells with an abnormal clone exceeds the normal reference range for any given probe
  • Positive result represents the detection of a higher number of abnormal signals compared to a normal reference for any given probe
  • The absence of a neoplastic or abnormal clone does not rule out the presence of a neoplastic disorder

Negative for chromosomal abnormalities

Conventional cytogenetic analysis, quantitative reverse transcriptase polymerase chain reaction (qRT-PCR), flow cytometry, Next-generation sequencing, microarray analysis In a clinical setting, the first step is cytogenetic analysis and a complete B-ALL FISH panel to identify the chromosomal abnormalities. Thereafter, conventional cytogenetic assessment and FISH with specific probes could be used to detect cryptic abnormality (not evident by conventional karyotyping), residual disease, early relapse, and follow-up of therapy.

2-3 ml of bone marrow (minimum value of 1 ml) or 5-10 ml of blood (minimum value of 2 ml) in a sodium heparinized vacutainer tube. The test usually performs on bone marrow samples, and sometimes on peripheral blood in the presence of leukemic cells (>15% blasts). Please mix the sample well with anticoagulant. Ship at ambient temperature within 24 hours of collection. Do not freeze or heat.

Stability

  • Ambient - 24 hours
  • Refrigerated - 3-5 days
  • Frozen - unacceptable
Morphological, histological, immunophenotypic (flow cytometric and/or immunohistochemical), and conventional cytogenetic analyses.
3-5 Days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login